Coronavirus Detection in the Clinical Microbiology Laboratory
Are We Ready for Identifying and Diagnosing a Novel Virus?

Katharine Uhteg, MS, Karen C. Carroll, MD, Heba H. Mostafa, MD, PhD, D(ABMM)*

INTRODUCTION

Coronaviruses were first described as viruses of animals, causing a wide spectrum of diseases that include gastroenteritis of pigs (transmissible gastroenteritis virus and porcine epidemic diarrhea virus), encephalitis in pigs (porcine hemagglutinating encephalomyelitis virus), lethal peritonitis in cats (feline infectious peritonitis virus),...
and bronchitis in chickens (infectious bronchitis virus). However, their potential to cause disease in humans was not described until the 1960s. Seven human coronaviruses (HCoVs) were identified, the first 2 of which, HCoV-OC43 and HCoV-229E, were isolated from patients with respiratory tract infections. Since then, these 2 coronaviruses were established as endemic strains associated with mild disease, and it was not until 2003 that a third HCoV was identified as a cause of severe acute respiratory syndrome (SARS). Two additional HCoVs were discovered in 2004 (HCoV-NL63) and 2005 (HCoV-HKU1), followed by the Middle East respiratory syndrome (MERS)-CoV, which emerged in 2012. Recently (December of 2019), the seventh HCoV (SARS-CoV-2) emerged in Wuhan, China, causing millions of confirmed cases with high mortality (the World Health Organization [WHO] has named the disease coronavirus disease 2019 [COVID-19]).

Coronaviruses belong to the family Coronaviridae order Nidovirales. Two subfamilies make up the Coronaviridae family: Letovirinae and Orthocoronavirinae. Orthocoronavirinae has 4 genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. Coronaviruses that infect mammals belong to the Alphacoronavirus and Betacoronavirus genera (Fig. 1).

ENDEMIC VERSUS HIGHLY PATHOGENIC CORONAVIRUSES

Four human coronaviruses have been established as endemic: HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1. These endemic strains have been identified as significant causes of acute respiratory infection and the common cold, causing 15% to 30% of respiratory tract infections each year. Infection with endemic coronaviruses can be severe, and the first isolation of HCoV-NL63 and HCoV-HKU1 were from cases of bronchiolitis and pneumonia. Although these endemic coronaviruses have the potential to cause severe disease, which is largely associated with immunocompromising conditions or young age, these viruses received scant attention because of their association with milder disease in immunocompetent individuals. The outbreak of SARS in China in 2002 to 2003 highlighted the potential of these and/or related viruses to cause outbreaks of severe disease, because more than 8000 cases were diagnosed with close to a 10% case fatality rate. This highly pathogenic strain that is thought to be transmitted to humans by direct contact with market civets was controlled after the 2003 outbreak with no additional cases reported since 2004. In 2012, another highly pathogenic coronavirus, MERS-CoV, was isolated from a patient with fatal pneumonia in Saudi Arabia. This virus was traced to dromedary camels. Apparently, frequent transmission events of this virus to this Middle East species of camel have occurred. This virus has affected 2494 individuals, with new cases being diagnosed every month, mainly from Saudi Arabia (WHO-MERS-CoV), with a case fatality rate higher than SARS-CoV (≈35%). In December 2019, a novel coronavirus (SARS-CoV-2) was first isolated from the city of Wuhan, China, and rapidly millions of cases were reported from almost every country in the world. This most novel coronavirus was characterized by extensive spread and apparently higher infectivity or more efficient human-to-human transmission. At the time of this submission (July 1, 2020), 511,860 deaths were associated with COVID-19 of a total of 10,501,482 confirmed global cases (https://coronavirus.jhu.edu/map.html).

Most of the animal and human coronaviruses are thought to originate from bats. Next-generation sequencing (NGS) of the bat virome revealed that 35% are coronaviruses, more than 200 of which were novel species. SARS-like CoV was isolated from the Chinese horseshoe bat years after the SARS-CoV outbreak, and MERS-CoV was found to be
related to viruses isolated from various bat species of the Vespertilionidae family. In addition, sequences similar to HCoV-NL63 and HCoV-229E have been identified in other species of bats. Because human coronaviruses all have zoonotic origin, it is essential to understand the determinants of spillover from bats or other natural reservoirs to humans. Surveillance studies with thorough genomic characterization are vital to predict the next novel highly pathogenic coronavirus epidemic.

**CORONAVIRUS GENOME**

The viruses of the *Coronaviridae* family are enveloped with a single-strand, positive-sense RNA genome that has an average size of 30 Kb. The name corona describes the crown-shaped projections of the surface when visualized with electron microscopy. The genome has a 5'-terminal cap similar to the standard eukaryotic cap structure and a polyadenylated tail at the 3' end. About two-thirds of the genome encodes for the replicase-transcriptase, which is the only protein that is immediately translated directly from the genome (encoded by open reading frames [ORFs] 1a and 1b, which encode for 16 nonstructural proteins) (Fig. 2). Negative-sense genomic and
subgenomic RNAs are then synthesized with the help of the replicase-transcriptase, which serve as the template for the production of all the downstream ORFs. At least 5 additional ORFs make up the remaining one-third of the genome and encode for structural proteins that include the spike (S), membrane (M), nucleocapsid (N), and envelope (E). Additional accessory genes are dispersed between the structural genes’ ORFs downstream of the replicase, which are group specific and required for efficient viral replication (see Fig. 2). Transcription regulatory sequences are located between the ORFs that control transcription termination as well as the addition of the leader sequences. The structural protein coding region by sequence alignment of different coronaviruses seems less conserved than the nonstructural protein encoding region; however, both regions show less than 60% identity at the genomic level. Usually, the more conserved Orf1b is selected as a target for molecular assay design.

**MOLECULAR DIAGNOSIS OF CORONAVIRUSES**

Nucleic acid detection methods are more sensitive than traditional methods of diagnosis that include cell culture, and offer higher specificity. In general, there are 3 goals...
of molecular coronavirus diagnosis in the clinical microbiology and public health laboratories: routine diagnostics of endemic strains, the diagnosis of highly pathogenic strains in endemic areas and during outbreaks, and the detection and characterization of novel unidentified viruses. For coronavirus molecular identification, assays that could generally detect all known human coronaviruses as well as assays that could distinguish the different species were developed. In addition, NGS has advanced the understanding of new coronaviruses and showed a great potential in their identification directly from clinical specimens, although these assays have not yet entered routine practice in the clinical laboratory.

**TARGETED CORONAVIRUS MOLECULAR DETECTION**

With the wide prevalence of endemic coronaviruses as significant causes of upper respiratory tract infection, implementing methods for routine diagnosis has become a common practice. At present, diagnosing coronaviruses in clinical microbiology laboratories is a part of most of the US Food and Drug Administration (FDA)–cleared respiratory panel assays (Table 1). These panels usually are supplemented with oligonucleotides specific for the 4 endemic HCoVs. These assays usually target the N gene; however, several laboratory-developed assays have used primers that target the polymerase, M or S genes, or the 5' untranslated region. Most of these assays are multiplex or nested real-time polymerase chain reaction (RT-PCR) tests. Because of their species specificity, these assays usually cannot identify novel coronaviruses. The FilmArray respiratory panel (BioFire Diagnostics, Salt Lake City, UT) and the ePlex Respiratory Pathogen Panel (GenMark Diagnostics, Carlsbad, CA) are currently two of the most commonly used extended respiratory panels. In addition to detecting the 4 endemic coronaviruses, the FilmArray Respiratory Panel 2 plus and the Pneumonia Panel plus have also incorporated specific primers for the detection of MERS-CoV. In addition, the BioFire Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 received FDA Emergency Use Authorization (EUA) for SARS-CoV-2 diagnosis. The QIAGEN QIAstat-Dx Respiratory SARS-CoV-2 Panel is an extended respiratory panel that also received an EUA for SARS-CoV-2 diagnosis.

Most clinical microbiology laboratories do not offer testing for targeted detection of highly pathogenic HCoVs in house, and, in outbreak situations, suspected specimens are sent out to either local public health laboratories or the US Centers for Disease Control and Prevention (CDC) (see Table 1). This work flow is challenging because of hurdles associated with specimen packaging and shipping in addition to prolonged turnaround times and their associated delay in making decisions related to patients’ isolation. In response to the recent outbreak of COVID-19, several groups nationally and internationally attempted to develop diagnostic assays that could be available for all clinical laboratories, and multiple diagnostic providers within the United States have been striving to receive EUA from the FDA. This response was secondary to the quick spread of the disease, but it was also largely facilitated by the availability of the virus genomic sequences very quickly early in the pandemic. RT-PCR assays developed by the Chinese National Institute for Viral Disease Control and Prevention, the University of Hong Kong, and the CDC (which received the EUA by FDA on February 4, 2020) were distributed on a large scale, followed by a very quick expansion in the number of the molecular EUA-approved tests. More than 100 assays are currently authorized for SARS-CoV-2 diagnosis, which are largely RT-PCR based. Other technologies have also received FDA authorization, including the CRISPR (clustered regularly interspaced short palindromic repeats)-based assay SHERLOCK (specific
| Assay                        | HCoVs Detected | Target                  | Testing Methodology                     | Primer Type | Comments          |
|-----------------------------|----------------|-------------------------|----------------------------------------|-------------|-------------------|
| Luminex Respiratory Pathogen Panel NxTAG | HCoV-NL63 | HCoV-NL63  | N gene | Multiplex RT-PCR and bead array hybridization | Specific | FDA cleared |
| BioFire FilmArray Respiratory Panel 2 plus | HCoV-NL63 | Not disclosed | Multiplex RT-PCR with melt curve analysis | Specific | FDA cleared |
| BioFire FilmArray Respiratory Panel 2.1 | HCoV-NL63 | HCoV-OC43  | HCoV-229E | HCoV-HKU1 | MERS-CoV | FDA-EUA |
| GenMark ePlex Respiratory Panel | HCoV-NL63 | N gene | Digital microfluidics with electrochemical detection | Specific | FDA cleared |
| Qiagen RespiFinder RG | HCoV-NL63 | N gene | Multiplex RT-PCR with melt curve analysis | Specific | FDA cleared |
| QIAGEN GmbH/Qiastat-Dx Respiratory SARS-Cov-2 Panel | HCoV-NL63 | HCoV-OC43 | HCoV-229E | HCoV-HKU1 | SARS-CoV-2 | FDA-EUA |
| CDC | MERS-CoV | UpE and ORF1α | RT-PCR | Specific |
|-----|---------|--------------|--------|---------|
|     |         |              |        | UpE: F (5'-GCAACGCGCGATTCAGTT-3') |
|     |         |              |        | R (5'-GCCTCTACACGGGACCATAA-3')  |
|     |         |              |        | P (5'6-FAM/CTCTTCACATAATCGCCCCGAGCTG/3'6-TAMSp) |
|     |         |              |        | ORF: F (5'- CCACACTCCCATTTCGTCAG-3') |
|     |         |              |        | R (5'- CAGTATGTTATGCTGCCGATATCA-3')  |
|     |         |              |        | P (5'6-FAM/TTGCAAATTGGCGTTCGCCCCCCTACT/3'6-TAMSp) |
| CDC | SARS-CoV | RNA polymerase, N gene | RT-PCR | Specific |
|     |         |              |        | SARS1: F (5'-CATGTGTGGGCGGCTCACTATAT-3') |
|     |         |              |        | R (5'-GACACTATTAGCATAAGCAGTGTAGCA-3')  |
|     |         |              |        | P (5'-TTAAACCAGGGGAAACTCATCCGGTG-3')  |
|     |         |              |        | SARS2: F (5'-GGAGCCTTGAATACACCCAAAG-3') |
|     |         |              |        | R (5'-GCACGGTGCGACACTTG-3')  |
|     |         |              |        | P (5'-CCACATTGGCACCAGCGAATCC-3')  |
|     |         |              |        | SARS3: F (5'-CAAACATTGGCCCCGAAATT-3') |
|     |         |              |        | R (5'-CAATGCGTGACATTCAGGAAG-3')  |
|     |         |              |        | P (5'-CACAATTGGCTCAAGTGCTCTGCA-3')  |
| CDC | SARS-CoV-2 | N gene | RT-PCR | Specific |
|     |         |              |        | N1: F (5'-GACCACCAATTCCAGGGAAT-3') |
|     |         |              |        | R (5'-TCTGGTTACTGGCAATGTTGCAATCTG-3')  |
|     |         |              |        | P (5'-FAM-ACCCCGCATATCGTTGTTGGACC-BHQ1-3')  |
|     |         |              |        | N2: F (5'-TTCAAACATTGGCCGCAAATG-3') |
|     |         |              |        | R (5'-GGCGGCAATTCCGAAGAA-3')  |
|     |         |              |        | P (5'-FAM-ACAATTGGCCCGAACAGTCGCT-CAG-BHQ1-3')  |
| Zhang, et al, 2018 | HCoV-NL63 | HCoV-NL63 | N gene | Multiplex RT-PCR | Specific |
|     | HCoV-OC43 | HCoV-OC43 |        |             | N1: F (5'-GTTCTTTCTGGTACCTTCCACTCT-3') |
|     | HCoV-229E | HCoV-229E |        |             | R (5'-TTCCACAGCAGTTGCTTCA-3')  |
|     | HCoV-HKU1 | HCoV-HKU1 |        |             | P (5'-FAM-ACCCCGCATTACGTTGTTGGACC-BHQ1-3')  |
|     |         |           |        |             | OC43: F (5'-CCCAAGTAGCGGTAGAGGTCA-3') |
|     |         |           |        |             | R (5'-AGGAGCAAGTCTTGGTACGGC-3')  |
|     |         |           |        |             | P (5'-FAM-ACCTAGGTCTTCGGCCTGCCAGGCT-A-BHQ1-3')  |
|     |         |           |        |             | Z29E: F (5'-CAGAAAACAGGAAGATTTGCTTCA-3') |
|     |         |           |        |             | R (5'-CAAGCAAAAGGGCTAATAAGAGA-3')  |
|     |         |           |        |             | P (5'-VIC-ATGGCTACAGTCAAATGGGCTGATGC-BHQ1-3')  |

(continued on next page)
Table 1 (continued)

| Assay      | HCoVs Detected | Target       | Testing Methodology  | Primer Type | Comments                                                                 |
|------------|----------------|--------------|----------------------|-------------|--------------------------------------------------------------------------|
| Gaunt et al,\(^{17}\) 2010 | HCoV-NL63 HCoV-OC43 HCoV-229E HCoV-HKU1 | HCoV-OC43 HCoV-229E HCoV-NL63 HCoV-HKU1 | M gene One-step multiplex RT-PCR Specific | NL63: F (5'-GGTTCTGATAAAGGCAACCATAAGG-3') R (5'-TCTTTAGGAACTAACTCAACAG-3') OC43: F (5'-CATACATCTAGGTGCAATAAAT-3') R (5'-ACCTCTAGCAACATCTATAAGC-3') 229E: F (5'-CATACATCTACCCATCTCAACAG-3') R (5'-CACGGCAACTGTGACTATT-3') HKU1: F (5'-TCCTACTAYTCAAGAAGCTATCC-3') R (5'-AATGAACCGGATATTGGTCCAC-3') |
| Vijgen et al,\(^{30}\) 2008 | HCoV-NL63 HCoV-OC43 HCoV-229E HCoV-HKU1 SARS-CoV | RdRp One-step RT-PCR Pan | F: (5'-ACWCARHTVAAYYNAAARTAYGC-3') R: (5'-TCRACAYTTDGGRTARTCCCA-3') |
| Canducci et al,\(^{53}\) 2008 | HCoV-NL63 HCoV-OC43 HCoV-229E HCoV-HKU1 SARS-CoV | RdRp RT-PCR Pan | F1: (5'-TTATGGGTTGGAATATCCYAARTTGATT-3') R1: (5'-AGGATGACTAGGAGAAGTYGTACCACC-3') F2: (5'-ATGGGATGAGCTAAGAAGCTATCC-3') R2: (5'-TTGCATCACATCTTGATGACCACCC-3') |

Abbreviations: CDC, US Centers for Disease Control and Prevention; EUA, Emergency Use Authorization; F, forward; M, membrane; N, nucleocapsid; P gene, polyprotein; P, probe; R, reverse; RdRp, RNA-dependent RNA polymerase; RT-PCR, real-time polymerase chain reaction; UpE, upstream E.
high-sensitivity enzymatic reporter unlocking) assay, which combined CRISPR with isothermal amplification as well as the COVIDSeq assay from Illumina (San Diego, CA), a targeted NGS-based assay. Globally, fast implementation of molecular diagnostics in Europe was remarkable, and several international commercial groups have quickly developed assays as well. These assays include a microarray panel developed by Veredus Laboratories (Singapore), which is an amplification-based array method for the quick detection of SARS-CoV, MERS-CoV, and SARS-CoV-2 (Vere-CoV detection kit), in addition to RT-PCR kits that were developed by Amoy Diagnostics (Xiamen, China), Altona Diagnostics (Hamburg, Germany), BGI group (Beijing Genomics Institute, Guangdong, China), among others. A list of all the EUA molecular SARS-CoV-2 assays is available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas.

One strategy for the detection of all species of coronaviruses requires the use of primers that are capable of recognizing conserved regions in the coronavirus genome. The polymerase gene has been used as a target for these pancoronavirus molecular amplification methods with variable analytical performance. In general, these assays are useful for the identification of novel coronaviruses and could be used for an initial screening; however, pancoronavirus detection approaches may suffer from lower sensitivity.

ARE CLINICAL LABORATORIES READY TO IDENTIFY A NOVEL CORONAVIRUS?

Coronaviruses as a cause of seasonal respiratory tract diseases are largely restricted to the 4 endemic human coronaviruses. To date, 3 epidemics have been caused by 3 novel highly pathogenic coronaviruses. The approaches for the initial characterization of these viruses varied. SARS-CoV was first identified by growing the virus in cell culture and using a random amplification polymerase chain reaction (PCR) assay to amplify a 300-nucleotide region. A diagnostic RT-PCR assay was developed based on the obtained sequence. A full genome was available shortly thereafter and multiple specific nucleic acid amplification diagnostic assays were developed. Conventional and molecular approaches were used for the classification of SARS-CoV as a member of Coronaviridae about 6 weeks after the Hong Kong outbreak in mid-February 2003. In 2012, the identification of MERS-CoV, which caused severe pneumonia and death of a 60-year-old man, was performed by a pan-CoV PCR assay after cell culture followed by amplicon sequencing. An assay panel was developed for the detection of the N nucleocapsid and the upstream sequence (up) to the E envelope (upe) genes, which has become the recommended test for the diagnosis of MERS-CoV by WHO. Eighteen years after the SARS-CoV outbreak, a novel coronavirus was recognized as a cause of another epidemic of severe respiratory infection that started in Wuhan, China. Shortly after the outbreak, clinical specimens were tested both by a pan-CoV PCR assay and NGS. Subsequently, a specific RT-PCR was developed. The SARS-CoV-2 whole genome was available on January 10, almost 1 month after the first report of pneumonia of unknown origin. This process was accelerated compared with SARS-CoV, of which a complete sequence was available in April 2003, a few months after the outbreak started late in 2002. The history of identifying novel epidemic coronaviruses highlights the great impact of using advanced metagenomic NGS (mNGS; discussed later) not only for rapid identification but also for the epidemiologic tracing of the viral reservoir and for elucidating the transmission dynamics.
METAGENOMIC NEXT-GENERATION SEQUENCING FOR CORONAVIRUS DIAGNOSIS

NGS is a high-throughput method that allows massive parallel sequencing of billions of DNA fragments simultaneously. mNGS is an unbiased, untargeted method for sequencing all genomes in a particular specimen. mNGS for viral identification in outbreak situations is very valuable in the absence of prior knowledge of the pathogen and facilitates quick phylogenetic characterization. mNGS has assisted in the characterization of SARS-CoV-2 from respiratory specimens in patients with pneumonia and has provided rapid insight into the genome and its phylogenetic relationship to other coronaviruses. As a response to this outbreak, a metagenomics deep-sequencing method using the MGI DNBSEQ-T7 sequencer (Cambridge, MA) for diagnosing coronaviruses in general was developed. This platform and the metagenomics coronavirus sequencing kit (BGI Group) have received an emergency use approval in China.

On the research side, mNGS was used to propose an evolutionary pathway of the SARS-CoV-2 virus from its origin in bats, for the detection of a cluster of severe lower respiratory tract infections associated with a novel subgenotype of HCoV-NL63, and in identifying an outbreak of health care–associated infections with HCoV-OC43 in hematopoietic stem cell transplant patients, in addition to illuminating a global understanding of the epidemiology of coronaviruses in bats. The applications of mNGS for identification and diagnosis of novel strains of coronaviruses are vast and, when used, initially will provide a quicker and better understanding of the biology and epidemiology of coronaviruses.

THIRD-GENERATION SEQUENCING: A PROMISING TOOL FOR RAPID DIAGNOSIS

A third-generation NGS instrument, the MinION, has become very popular and is a promising tool for developing point-of-care mNGS methods. The MinION is a portable sequencer that uses the innovative Nanopore protein pores for sequencing. Strands of DNA or RNA are directed to the protein pores and a characteristic change in the electric current distinguishes nucleotide bases. Easy-to-prepare libraries and real-time analysis facilitate the use of MinION as a clinical diagnostic tool. Nanopore recently released Flongle, a flow cell designed for individual tests with less cost. This addition will further enhance the potential of the clinical implementation of this technology.

Several studies have shown the great potential of MinION in viral identification and confirmed its potential as a point-of-care test, which included the identification of chikungunya, Ebola, and hepatitis C. Recently, diagnosis of influenza virus using MinION directly from respiratory specimens was successful, with excellent sensitivity from specimens with higher viral loads. In addition, a near-complete influenza viral genome was reconstructed by MinION in this study as well as the detection of coinfecting viruses that included coronavirus and human metapneumovirus.

The characterization of the most recent highly pathogenic coronavirus (SARS-CoV-2) was partially performed by MinION sequencing in addition to mNGS. In addition, MinION was used in combination with Sanger-based sequencing for the prospective analysis of specimens from suspected patients in Wuhan in order to characterize the epidemiology of SARS-CoV-2 transmission and to determine the potential for human-to-human transmission.

The use of the MinION as a tool for quick investigation of a novel coronavirus has not only diagnostic potential but also a huge epidemiologic impact. A quick method for direct sequencing of clinical specimens is instrumental for understanding the transmission of the virus, its mutation rate, and polymorphisms associated with disease
severity. The ARTIC network was initiated by a group of molecular biologists as a real-time molecular epidemiology response network for processing specimens during viral outbreaks. Based on Nanopore technology, this epidemiologic screening network for viral outbreaks has become feasible in locations with limited resources and is mainly focused on the rapidly evolving RNA viruses. The overall goal is to collect sequencing information in a real-time format to allow the real-time understanding of viral transmission and evolution (https://artic.network/). The ARTIC group has started providing materials and support for sequencing the SARS-CoV-2, which include primers, protocols, and pipelines for data analysis.

Another advantage to using Nanopore sequencing methods is the feasibility of direct RNA sequencing. This approach was used to obtain the whole genome of HCoV-229E and was very successful in identifying not only an accurately built scaffold for the genome but also the several subgenomic-length RNAs. Like other RNA viruses, coronaviruses are characterized by high rates of recombination in addition to the unique replication cycle that results in nested messenger RNAs, largely identical to the original sequence. With the existence of this complex population of variants, long reads sequencing becomes the method of choice. Future research using NGS approaches might give further insight into the biology of replication and polymorphisms of coronaviruses. This method still faces the challenges of high error rate, approaches for maintaining the integrity of RNA samples, and the requirement for high-input RNA.

**DISCUSSION**

Rapidly emerging viral outbreaks pose a great challenge to clinical laboratories for quickly developing assays with high sensitivity and specificity for diagnosis and infection control. Molecular methods have rapidly replaced traditional methods and assisted the laboratories in real-time epidemiologic surveillance in outbreak situations. The recent outbreak of the novel coronavirus SARS-CoV-2 highlighted a great advance in the molecular diagnosis of evolving viral pathogens. Metagenomics, facilitated by innovative sequencing methodologies, is driving faster pathogen characterization and epidemiologic investigations. Because of the challenges in developing a PCR assay that has the potential for detecting all species of evolving RNA viruses, including coronaviruses, an approach that aims at implementing mNGS directly from clinical specimens along with complementary molecular diagnostic methods is most appropriate for clinically and epidemiologically managing a novel coronavirus outbreak. It is not currently possible to rapidly identify a novel coronavirus, but methodologies are being quickly developed that will change the current workflow in response to an emergent viral strain.

**DISCLOSURE**

The authors have nothing to disclose.

**REFERENCES**

1. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23.
2. Corman VM, Muth D, Niemeyer D, et al. Hosts and sources of endemic human coronaviruses. Adv Virus Res 2018;100:163–88.
3. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966;121:190–3.
4. McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A 1967;57:933–40.

5. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.

6. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394–9.

7. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004;10:368–73.

8. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005;79:884–95.

9. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20.

10. Hui DS, Esam IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020;91:264–6.

11. Woo PC, Huang Y, Lau SK, et al. Coronavirus genomics and bioinformatics analysis. Viruses 2010;2:1804–20.

12. van Elden LJ, van Loon AM, van Alphen F, et al. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis 2004;189:652–7.

13. Owusu M, Annan A, Corman VM, et al. Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana. PLoS One 2014;9:e99782.

14. Annan A, Ebach F, Corman VM, et al. Similar virus spectra and seasonality in pediatric patients with acute respiratory disease, Ghana and Germany. Clin Microbiol Infect 2016;22:340–6.

15. Arden KE, Nissen MD, Sloots TP, et al. New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia. J Med Virol 2005;75:455–62.

16. Bastien N, Robinson JL, Tse A, et al. Human coronavirus NL-63 infections in children: a 1-year study. J Clin Microbiol 2005;43:4567–73.

17. Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 2010;48:2940–7.

18. Konca C, Korukluoglu G, Tekin M, et al. The first infant death associated with human coronavirus NL63 infection. Pediatr Infect Dis J 2017;36:231–3.

19. Mayer K, Nellessen C, Hahn-Ast C, et al. Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN-alpha in a patient with newly diagnosed ALL. Eur J Haematol 2016;97:208–10.

20. Oosterhof L, Christensen CB, Sengelov H. Fatal lower respiratory tract disease with human coronavirus NL63 in an adult haematopoietic cell transplant recipient. Bone Marrow Transplant 2010;45:1115–6.

21. Cheng VC, Lau SK, Woo PC, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007;20:660–94.
22. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276–8.

23. Chu DK, Poon LL, Gomaa MM, et al. MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis 2014;20:1049–53.

24. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013;13:859–66.

25. Banerjee A, Kulcsar K, Misra V, et al. Bats and coronaviruses. Viruses 2019;11(1):41. Available at: https://www.mdpi.com/1999-4915/11/1/41. Accessed January 9, 2019.

26. Anthony SJ, Gilardi K, Menachery VD, et al. Further evidence for bats as the evolutionary source of middle east respiratory syndrome coronavirus. mBio 2017;8. e00373-17.

27. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol 2007;81:20–9.

28. Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci 2011;48:217–49.

29. Reusken C, Broberg EK, Haagmans B, et al. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Euro Surveill 2020;25:2000082.

30. Vijgen L, Moes E, Keyaerts E, et al. A pancoronavirus RT-PCR assay for detection of all known coronaviruses. Methods Mol Biol 2008;454:3–12.

31. Zlateva KT, Coenjaerts FE, Crusio KM, et al. No novel coronaviruses identified in a large collection of human nasopharyngeal specimens using family-wide CODE-HOP-based primers. Arch Virol 2013;158:251–5.

32. Gerna G, Campanini G, Rovida F, et al. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J Med Virol 2006;78:938–49.

33. Mahony JB, Richardson S. Molecular diagnosis of severe acute respiratory syndrome: the state of the art. J Mol Diagn 2005;7:551–9.

34. Chow KY, Hon CC, Hui RK, et al. Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Genomics Proteomics Bioinformatics 2003;1:247–62.

35. Lu X, Whitaker B, Sakthivel SK, et al. Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. J Clin Microbiol 2014;52:67–75.

36. Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol 2019;14:319–38.

37. Benvenuto D, Giovanetti M, Ciccozzi A, et al. The 2019-new coronavirus epidemic: evidence for virus evolution. J Med Virol 2020. https://doi.org/10.1002/jmv.25688.

38. Wang Y, Li X, Liu W, et al. Discovery of a subgenotype of human coronavirus NL63 associated with severe lower respiratory tract infection in China, 2018. Emerg Microbes Infect 2020;9:246–55.

39. Beury D, Flechon L, Maurier F, et al. Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit. J Clin Virol 2020;122:104206.

40. Wong ACP, Li X, Lau SKP, et al. Global epidemiology of bat coronaviruses. Viruses 2019;11:174.
41. Laver T, Harrison J, O’Neill PA, et al. Assessing the performance of the oxford nanopore technologies MinION. Biomol Detect Quantif 2015;3:1–8.
42. Kilianski A, Haas JL, Corriveau EJ, et al. Bacterial and viral identification and differentiation by amplicon sequencing on the MinION nanopore sequencer. Giga-science 2015;4:12.
43. Greninger AL, Naccache SN, Federman S, et al. Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis. Genome Med 2015;7:99.
44. Lewandowski K, Xu Y, Pullan ST, et al. Metagenomic nanopore sequencing of influenza virus direct from clinical respiratory samples. J Clin Microbiol 2019;58. e00963-19.
45. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2001017.
46. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020. https://doi.org/10.1016/S0140-6736(20)30154-9.
47. Itokawa K, Sekizuka T, Hashino M, et al. A proposal of an alternative primer for the ARTIC Network’s multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing. bioRxiv 2020. https://doi.org/10.1101/2020.03.10.985150.2020.2003.2010.985150.
48. Viehweger A, Krautwurst S, Lamkiewicz K, et al. Direct RNA nanopore sequencing of full-length coronavirus genomes provides novel insights into structural variants and enables modification analysis. Genome Res 2019;29:1545–54.
49. Liao CL, Lai MM. RNA recombination in a coronavirus: recombination between viral genomic RNA and transfected RNA fragments. J Virol 1992;66:6117–24.
50. Hemida MG, Chu DK, Poon LL, et al. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 2014;20:1231–4.
51. Emery SL, Erdman DD, Bowen MD, et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis 2004;10:311–6.
52. Zhang D, Mao HY, Lou XY, et al. Clinical evaluation of a panel of multiplex quantitative real-time reverse transcription polymerase chain reaction assays for the detection of 16 respiratory viruses associated with community-acquired pneumonia. Arch Virol 2018;163:2855–60.
53. Canducci F, Debiaggi M, Sampaolo M, et al. Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. J Med Virol 2008;80:716–23.